ClinicalTrials.gg

Program

DONQ52

A development code.

In Hoffmann-La Roche's pipeline, anti-HLA-DQ2.5 x gluten peptides. Its studies are mostly in Celiac Disease, led by Hoffmann-La Roche.

Furthest: phase 2, since Nov 16, 20252 company-led studies, 1 open or runningNext primary completion: Jun 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche21 open or runningphase 2since Nov 16, 2025Jun 13, 2022Jun 15, 2027phase 2 · NCT07239336
  • Named in Hoffmann-La Roche’s own pipeline as CHU anti-HLA-DQ2.5 x gluten peptides, phase 2, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2022First study: phase 1 study in Celiac DiseaseFirst studyNCT05425446 · 56 enrolled · United States, Australia
  2. Nov 16, 2025Phase 2 study in Celiac DiseasePhase 2 reachedNCT07239336 · 92 planned · United States, Australia, New Zealand

Ahead

  1. Jun 15, 2027Primary completion: phase 2 study in Celiac DiseaseNCT07239336

TargetBeta

“anti-HLA-DQ2.5 x gluten peptides”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07239336Celiac Disease · United States, Australia, New Zealand2RecruitingJun 15, 202792
NCT05425446Celiac Disease · United States, Australia1CompletedAug 9, 202456

How it is read

Names in the registry

  • “DONQ52”, 2 entries

Codes read as this program: DONQ52.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.